{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:11:09Z","timestamp":1793866269886,"version":"4.6.1"},"reference-count":145,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1038\/s41585-020-0346-4","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T06:02:53Z","timestamp":1594879373000},"page":"513-525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":197,"title":["Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3079-027X","authenticated-orcid":false,"given":"Jelmer H.","family":"van Puffelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-0018","authenticated-orcid":false,"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-6052","authenticated-orcid":false,"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6166-9830","authenticated-orcid":false,"given":"Leo A. B.","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4913-8601","authenticated-orcid":false,"given":"Sita H.","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"346_CR1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D. & Bruce, A. W. Intracavitary bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180\u2013183 (1976).","journal-title":"J. Urol."},{"key":"346_CR2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BLC-150034","volume":"2","author":"NE Power","year":"2016","unstructured":"Power, N. E. & Izawa, J. Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bladder Cancer 2, 27\u201336 (2016).","journal-title":"Bladder Cancer"},{"key":"346_CR3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk, M. et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2014 2019 update. Eur. Urol. 76, 639\u2013657 (2019).","journal-title":"Eur. Urol."},{"key":"346_CR4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","volume":"88","author":"MD Shelley","year":"2001","unstructured":"Shelley, M. D. et al. A systematic review of intravesical bacillus Calmette\u2013Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 88, 209\u2013216 (2001).","journal-title":"BJU Int."},{"key":"346_CR5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley, M. D. et al. Intravesical bacillus Calmette\u2013Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 93, 485\u2013490 (2004).","journal-title":"BJU Int."},{"key":"346_CR6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester, R. J., van der Meijden, A. P., Witjes, J. A. & Kurth, K. Bacillus Calmette\u2013Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174, 86\u201391 (2005).","journal-title":"J. Urol."},{"key":"346_CR7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester, R. J., van der, M. A. & Lamm, D. L. Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964\u20131970 (2002).","journal-title":"J. Urol."},{"key":"346_CR8","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han, R. F. & Pan, J. G. Can intravesical bacillus Calmette\u2013Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67, 1216\u20131223 (2006).","journal-title":"Urology"},{"key":"346_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette\u2013Guerin. Eur. Urol. 69, 60\u201369 (2016).","journal-title":"Eur. Urol."},{"key":"346_CR10","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","volume":"191","author":"T Hemdan","year":"2014","unstructured":"Hemdan, T. et al. 5-Year outcome of a randomized prospective study comparing bacillus Calmette\u2013Guerin with epirubicin and interferon-alpha2b in\u00a0patients with T1 bladder cancer. J. Urol. 191, 1244\u20131249 (2014).","journal-title":"J. Urol."},{"key":"346_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer \u2014 a current perspective. Nat. Rev. Urol. 11, 153\u2013162 (2014).","journal-title":"Nat. Rev. Urol."},{"key":"346_CR12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","volume":"15","author":"C Pettenati","year":"2018","unstructured":"Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615\u2013625 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"346_CR13","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1111\/bju.12334","volume":"113","author":"S Jallad","year":"2014","unstructured":"Jallad, S., Goubet, S., Symes, A., Larner, T. & Thomas, P. Prognostic value of inflammation or granuloma after intravesical BCG in non-muscle-invasive bladder cancer. BJU Int. 113, E22\u2013E27 (2014).","journal-title":"BJU Int."},{"key":"346_CR14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1023\/A:1019533806868","volume":"33","author":"E Pieras-Ayala","year":"2001","unstructured":"Pieras-Ayala, E. et al. Prognostic value of cystocopically pseudotumoral lesions (inflammation\/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int. Urol. Nephrol. 33, 469\u2013472 (2001).","journal-title":"Int. Urol. Nephrol."},{"key":"346_CR15","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","volume":"181","author":"A Bisiaux","year":"2009","unstructured":"Bisiaux, A. et al. Molecular analyte profiling of the\u00a0early events and tissue conditioning following intravesical bacillus Calmette\u2013Guerin therapy in patients with superficial bladder cancer. J. Urol. 181, 1571\u20131580 (2009).","journal-title":"J. Urol."},{"key":"346_CR16","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","volume":"107","author":"F Saint","year":"2003","unstructured":"Saint, F. et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette\u2013Guerin response of superficial bladder cancer during induction course and\u00a0maintenance therapy. Int. J. Cancer 107, 434\u2013440 (2003).","journal-title":"Int. J. Cancer"},{"key":"346_CR17","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","volume":"167","author":"F Saint","year":"2002","unstructured":"Saint, F. et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette\u2013Guerin treatment for superficial bladder cancer. J. Urol. 167, 364\u2013367 (2002).","journal-title":"J. Urol."},{"key":"346_CR18","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1128\/CVI.00349-16","volume":"23","author":"S Bekkering","year":"2016","unstructured":"Bekkering, S. et al. In vitro experimental model of trained innate immunity in human primary monocytes. Clin. Vaccine Immunol. 23, 926\u2013933 (2016).","journal-title":"Clin. Vaccine Immunol."},{"key":"346_CR19","doi-asserted-by":"crossref","first-page":"1250684","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng, S. C. et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).","journal-title":"Science"},{"key":"346_CR20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1089\/ars.2017.7310","volume":"29","author":"C van der Heijden","year":"2018","unstructured":"van der Heijden, C. et al. Epigenetics and trained immunity. Antioxid. Redox Signal. 29, 1023\u20131040 (2018).","journal-title":"Antioxid. Redox Signal."},{"key":"346_CR21","doi-asserted-by":"crossref","first-page":"1251086","DOI":"10.1126\/science.1251086","volume":"345","author":"S Saeed","year":"2014","unstructured":"Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).","journal-title":"Science"},{"key":"346_CR22","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: a program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"346_CR23","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.celrep.2016.11.011","volume":"17","author":"RJW Arts","year":"2016","unstructured":"Arts, R. J. W. et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep. 17, 2562\u20132571 (2016).","journal-title":"Cell Rep."},{"key":"346_CR24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1189\/jlb.4MA0215-059R","volume":"98","author":"RJ Arts","year":"2015","unstructured":"Arts, R. J. et al. Long-term in vitro and in vivo effects of gamma-irradiated BCG on innate and adaptive immunity. J. Leukoc. Biol. 98, 995\u20131001 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"346_CR25","first-page":"4058","volume":"125","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. MLL1, a H3K4 methyltransferase, regulates the TNFalpha-stimulated activation of genes downstream of NF-kappaB. J. Cell Sci. 125,\u00a04058\u20134066 (2012).","journal-title":"J. Cell Sci."},{"key":"346_CR26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.immuni.2012.02.016","volume":"36","author":"L Austenaa","year":"2012","unstructured":"Austenaa, L. et al. The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity 36, 572\u2013585 (2012).","journal-title":"Immunity"},{"key":"346_CR27","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.2337\/db17-0194","volume":"66","author":"AS Kimball","year":"2017","unstructured":"Kimball, A. S. et al. The histone methyltransferase MLL1 directs macrophage-mediated inflammation in wound healing and is altered in a murine model of\u00a0obesity and type 2 diabetes. Diabetes 66, 2459\u20132471 (2017).","journal-title":"Diabetes"},{"key":"346_CR28","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.1202870109","volume":"109","author":"J Kleinnijenhuis","year":"2012","unstructured":"Kleinnijenhuis, J. et al. Bacille Calmette\u2013Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc. Natl Acad. Sci. USA 109, 17537\u201317542 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"346_CR29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1189\/jlb.6AB0914-416R","volume":"98","author":"RJ Arts","year":"2015","unstructured":"Arts, R. J. et al. Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes. J. Leukoc. Biol. 98, 129\u2013136 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"346_CR30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1161\/CIRCRESAHA.116.303936","volume":"116","author":"ST Keating","year":"2015","unstructured":"Keating, S. T. & El-Osta, A. Epigenetics and metabolism. Circ. Res. 116, 715\u2013736 (2015).","journal-title":"Circ. Res."},{"key":"346_CR31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.cmet.2016.10.008","volume":"24","author":"RJ Arts","year":"2016","unstructured":"Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807\u2013819 (2016).","journal-title":"Cell Metab."},{"key":"346_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","volume":"23","author":"RJW Arts","year":"2018","unstructured":"Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89\u2013100 (2018).","journal-title":"Cell Host Microbe"},{"key":"346_CR33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004485","volume":"10","author":"K Buffen","year":"2014","unstructured":"Buffen, K. et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 10, e1004485 (2014).","journal-title":"PLoS Pathog."},{"key":"346_CR34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000355628","volume":"6","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis, J. et al. Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity. J. Innate Immun. 6, 152\u2013158 (2014).","journal-title":"J. Innate Immun."},{"key":"346_CR35","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ncb1007-1102","volume":"9","author":"Z Xie","year":"2007","unstructured":"Xie, Z. & Klionsky, D. J. Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 9, 1102\u20131109 (2007).","journal-title":"Nat. Cell Biol."},{"key":"346_CR36","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.3273","volume":"16","author":"ST Shibutani","year":"2015","unstructured":"Shibutani, S. T., Saitoh, T., Nowag, H., Munz, C. & Yoshimori, T. Autophagy and autophagy-related proteins in the immune system. Nat. Immunol. 16, 1014\u20131024 (2015).","journal-title":"Nat. Immunol."},{"key":"346_CR37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/2049-632X.12023","volume":"67","author":"EK Jo","year":"2013","unstructured":"Jo, E. K. Autophagy as an innate defense against mycobacteria. Pathog. Dis. 67, 108\u2013118 (2013).","journal-title":"Pathog. Dis."},{"key":"346_CR38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.tube.2012.05.004","volume":"92","author":"M Songane","year":"2012","unstructured":"Songane, M., Kleinnijenhuis, J., Netea, M. G. & van Crevel, R. The role of autophagy in host defence against Mycobacterium tuberculosis infection. Tuberculosis 92, 388\u2013396 (2012).","journal-title":"Tuberculosis"},{"key":"346_CR39","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.1074\/jbc.M111.320135","volume":"287","author":"AJ Zullo","year":"2012","unstructured":"Zullo, A. J. & Lee, S. Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of rapamycin inhibition. J. Biol. Chem. 287, 12668\u201312678 (2012).","journal-title":"J. Biol. Chem."},{"key":"346_CR40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1462-5822.2010.01544.x","volume":"13","author":"MN Brooks","year":"2011","unstructured":"Brooks, M. N. et al. NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages. Cell. Microbiol. 13, 402\u2013418 (2011).","journal-title":"Cell. Microbiol."},{"key":"346_CR41","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1128\/IAI.00334-16","volume":"84","author":"M Schenk","year":"2016","unstructured":"Schenk, M. et al. Human NOD2 recognizes structurally unique muramyl dipeptides from Mycobacterium leprae. Infect. Immun. 84, 2429\u20132438 (2016).","journal-title":"Infect. Immun."},{"key":"346_CR42","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.4049\/jimmunol.178.4.2380","volume":"178","author":"J-H Park","year":"2007","unstructured":"Park, J.-H. et al. RICK\/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J. Immunol. 178, 2380\u20132386 (2007).","journal-title":"J. Immunol."},{"key":"346_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/iid3.9","volume":"1","author":"ML Bourigault","year":"2013","unstructured":"Bourigault, M. L. et al. Relative contribution of IL-1alpha, IL-1beta and TNF to the host response to Mycobacterium tuberculosis and attenuated M. bovis BCG. Immun. Inflamm. Dis. 1, 47\u201362 (2013).","journal-title":"Immun. Inflamm. Dis."},{"key":"346_CR44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cell.2017.11.034","volume":"172","author":"I Mitroulis","year":"2018","unstructured":"Mitroulis, I. et al. Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172, 147\u2013161 (2018).","journal-title":"Cell"},{"key":"346_CR45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2017.12.031","volume":"172","author":"E Kaufmann","year":"2018","unstructured":"Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176\u2013190 (2018).","journal-title":"Cell"},{"key":"346_CR46","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nri3062","volume":"11","author":"KY King","year":"2011","unstructured":"King, K. Y. & Goodell, M. A. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685\u2013692 (2011).","journal-title":"Nat. Rev. Immunol."},{"key":"346_CR47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.shk.0000223125.56888.c7","volume":"26","author":"AQ Wen","year":"2006","unstructured":"Wen, A. Q. et al. Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. Shock 26, 25\u201330 (2006).","journal-title":"Shock"},{"key":"346_CR48","first-page":"517","volume":"53","author":"MI Levine","year":"1946","unstructured":"Levine, M. I. & Sackett, M. F. Results of BCG immunization in New York City. Am. Rev. Tuberc. 53, 517\u2013532 (1946).","journal-title":"Am. Rev. Tuberc."},{"key":"346_CR49","first-page":"1336","volume":"31","author":"JD Aronson","year":"1948","unstructured":"Aronson, J. D. Protective vaccination against tuberculosis, with special reference to BCG vaccine. Minn. Med. 31, 1336 (1948).","journal-title":"Minn. Med."},{"key":"346_CR50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0041-3879(49)80055-9","volume":"30","author":"RG Ferguson","year":"1949","unstructured":"Ferguson, R. G. & Simes, A. B. BCG vaccination of Indian infants in Saskatchewan. Tubercle 30, 5\u201311 (1949).","journal-title":"Tubercle"},{"key":"346_CR51","first-page":"690","volume":"84","author":"SR Rosenthal","year":"1961","unstructured":"Rosenthal, S. R. et al. BCG vaccination in tuberculous households. Am. Rev. Respir. Dis. 84, 690\u2013704 (1961).","journal-title":"Am. Rev. Respir. Dis."},{"key":"346_CR52","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","volume":"367","author":"BB Trunz","year":"2006","unstructured":"Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173\u20131180 (2006).","journal-title":"Lancet"},{"key":"346_CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/infdis\/jir240","volume":"204","author":"P Aaby","year":"2011","unstructured":"Aaby, P. et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J. Infect. Dis. 204, 245\u2013252 (2011).","journal-title":"J. Infect. Dis."},{"key":"346_CR54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/INF.0b013e3182458289","volume":"31","author":"S Biering-Sorensen","year":"2012","unstructured":"Biering-Sorensen, S. et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette\u2013Guerin vaccination at first health center contact. Pediatr. Infect. Dis. J. 31, 306\u2013308 (2012).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"346_CR55","doi-asserted-by":"crossref","first-page":"i5170","DOI":"10.1136\/bmj.i5170","volume":"355","author":"JP Higgins","year":"2016","unstructured":"Higgins, J. P. et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 355, i5170 (2016).","journal-title":"BMJ"},{"key":"346_CR56","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.cmi.2019.04.020","volume":"25","author":"S Moorlag","year":"2019","unstructured":"Moorlag, S., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473\u20131478 (2019).","journal-title":"Clin. Microbiol. Infect."},{"key":"346_CR57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08659-3","volume":"10","author":"J Walk","year":"2019","unstructured":"Walk, J. et al. Outcomes of controlled human malaria infection after BCG vaccination. Nat. Commun. 10, 874 (2019).","journal-title":"Nat. Commun."},{"key":"346_CR58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clim.2014.10.005","volume":"155","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis, J. et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin. Immunol. 155, 213\u2013219 (2014).","journal-title":"Clin. Immunol."},{"key":"346_CR59","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/j.1365-3083.1992.tb03132.x","volume":"36","author":"JW van \u2018t Wout","year":"1992","unstructured":"van \u2018t Wout, J. W., Poell, R. & van Furth, R. The role of BCG\/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand. J. Immunol. 36, 713\u2013719 (1992).","journal-title":"Scand. J. Immunol."},{"key":"346_CR60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"346_CR61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF01517205","volume":"38","author":"P Conti","year":"1994","unstructured":"Conti, P. et al. Bacillus Calmette\u2013Guerin potentiates monocyte responses to lipopolysaccharide-induced tumor necrosis factor and interleukin-1, but not interleukin-6 in bladder cancer patients. Cancer Immunol. Immunother. 38, 365\u2013371 (1994).","journal-title":"Cancer Immunol. Immunother."},{"key":"346_CR62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3349\/ymj.1993.34.4.356","volume":"34","author":"CI Kim","year":"1993","unstructured":"Kim, C. I., Shin, J. S., Kim, H. I., Lee, J. M. & Kim, S. J. Production of tumor necrosis factor by intravesical administration of bacillus Calmette\u2013Guerin in patients with superficial bladder cancer. Yonsei Med. J. 34, 356\u2013364 (1993).","journal-title":"Yonsei Med. J."},{"key":"346_CR63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20517\/2394-4722.2017.25","volume":"3","author":"FM Calais da Silva","year":"2017","unstructured":"Calais da Silva, F. M. et al. Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more. J. Cancer Metastasis Treat. 3, 116\u2013126 (2017).","journal-title":"J. Cancer Metastasis Treat."},{"key":"346_CR64","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1373\/clinchem.2015.240531","volume":"61","author":"K Adeli","year":"2015","unstructured":"Adeli, K. et al. Complex biological profile of hematologic markers across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures survey. Clin. Chem. 61, 1075\u20131086 (2015).","journal-title":"Clin. Chem."},{"key":"346_CR65","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2249.2006.03288.x","volume":"147","author":"Y Luo","year":"2007","unstructured":"Luo, Y., Chen, X. & O\u2019Donnell, M. A. Mycobacterium bovis bacillus Calmette\u2013Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin. Exp. Immunol. 147, 370\u2013378 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"346_CR66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33253-w","volume":"8","author":"E Noguera-Ortega","year":"2018","unstructured":"Noguera-Ortega, E. et al. Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Sci. Rep. 8, 15102 (2018).","journal-title":"Sci. Rep."},{"key":"346_CR67","doi-asserted-by":"crossref","first-page":"137ra172","DOI":"10.1126\/scitranslmed.3003586","volume":"4","author":"C Biot","year":"2012","unstructured":"Biot, C. et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci. Transl Med. 4, 137ra172 (2012).","journal-title":"Sci. Transl Med."},{"key":"346_CR68","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","volume":"14","author":"Y Shintani","year":"2007","unstructured":"Shintani, Y. et al. Intravesical instillation therapy with bacillus Calmette\u2013Guerin for superficial bladder cancer: study of the mechanism of bacillus Calmette\u2013Guerin immunotherapy. Int. J. Urol. 14, 140\u2013146 (2007).","journal-title":"Int. J. Urol."},{"key":"346_CR69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","volume":"115","author":"K Taniguchi","year":"1999","unstructured":"Taniguchi, K. et al. Systemic immune response after intravesical instillation of bacille Calmette\u2013Guerin (BCG) for superficial bladder cancer. Clin. Exp. Immunol. 115, 131\u2013135 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"346_CR70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","volume":"69","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette\u2013Guerin. Eur. Urol. 69, 197\u2013200 (2016).","journal-title":"Eur. Urol."},{"key":"346_CR71","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM de Reijke","year":"1996","unstructured":"de Reijke, T. M., de Boer, E. C., Kurth, K. H. & Schamhart, D. H. Urinary cytokines during intravesical bacillus Calmette\u2013Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. 155, 477\u2013482 (1996).","journal-title":"J. Urol."},{"key":"346_CR72","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-5347(01)62065-2","volume":"161","author":"TM de Reijke","year":"1999","unstructured":"de Reijke, T. M., De Boer, E. C., Kurth, K. H. & Schamhart, D. H. Urinary interleukin-2 monitoring during prolonged bacillus Calmette\u2013Guerin treatment: can it predict the optimal number of instillations? J. Urol. 161, 67\u201371 (1999).","journal-title":"J. Urol."},{"key":"346_CR73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-001-0254-2","volume":"51","author":"M Reale","year":"2002","unstructured":"Reale, M. et al. Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette\u2013Guerin immunotherapy. Cancer Immunol. Immunother. 51, 91\u201398 (2002).","journal-title":"Cancer Immunol. Immunother."},{"key":"346_CR74","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00345-014-1458-3","volume":"33","author":"TJH Arends","year":"2015","unstructured":"Arends, T. J. H. et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J. Urol. 33, 1411\u20131417 (2015).","journal-title":"World J. Urol."},{"key":"346_CR75","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/nature05836","volume":"447","author":"SL Foster","year":"2007","unstructured":"Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972\u2013978 (2007).","journal-title":"Nature"},{"key":"346_CR76","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.immuni.2016.10.012","volume":"45","author":"K Toyonaga","year":"2016","unstructured":"Toyonaga, K. et al. C-type lectin receptor DCAR recognizes mycobacterial phosphatidyl-inositol mannosides to promote a Th1 response during infection. Immunity 45, 1245\u20131257 (2016).","journal-title":"Immunity"},{"key":"346_CR77","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.4049\/jimmunol.177.3.1805","volume":"177","author":"JB Torrelles","year":"2006","unstructured":"Torrelles, J. B., Azad, A. K. & Schlesinger, L. S. Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J. Immunol. 177, 1805\u20131816 (2006).","journal-title":"J. Immunol."},{"key":"346_CR78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.immuni.2014.08.005","volume":"41","author":"A Yonekawa","year":"2014","unstructured":"Yonekawa, A. et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity 41, 402\u2013413 (2014).","journal-title":"Immunity"},{"key":"346_CR79","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.it.2016.10.009","volume":"38","author":"E Ishikawa","year":"2017","unstructured":"Ishikawa, E., Mori, D. & Yamasaki, S. Recognition of mycobacterial lipids by immune receptors. Trends Immunol. 38, 66\u201376 (2017).","journal-title":"Trends Immunol."},{"key":"346_CR80","doi-asserted-by":"crossref","first-page":"iii6","DOI":"10.1136\/ard.60.1.6","volume":"60","author":"BW Jones","year":"2001","unstructured":"Jones, B. W., Heldwein, K. A., Means, T. K., Saukkonen, J. J. & Fenton, M. J. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann. Rheumatic Dis. 60, iii6\u2013iii12 (2001).","journal-title":"Ann. Rheumatic Dis."},{"key":"346_CR81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1189\/jlb.69.6.1036","volume":"69","author":"BW Jones","year":"2001","unstructured":"Jones, B. W. et al. Different Toll-like receptor agonists induce distinct macrophage responses. J. Leukoc. Biol. 69, 1036\u20131044 (2001).","journal-title":"J. Leukoc. Biol."},{"key":"346_CR82","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13238-016-0326-x","volume":"8","author":"R Yan","year":"2017","unstructured":"Yan, R. & Liu, Z. LRRK2 enhances Nod1\/2-mediated inflammatory cytokine production by promoting Rip2 phosphorylation. Protein Cell 8, 55\u201366 (2017).","journal-title":"Protein Cell"},{"key":"346_CR83","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2012.1","volume":"1","author":"E de Jong","year":"2012","unstructured":"de Jong, E., Lim, A., Waterer, G. & Price, P. Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease. Clin. Transl Immunol. 1, e2 (2012).","journal-title":"Clin. Transl Immunol."},{"key":"346_CR84","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ni1028","volume":"5","author":"E Latz","year":"2004","unstructured":"Latz, E. et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5, 190\u2013198 (2004).","journal-title":"Nat. Immunol."},{"key":"346_CR85","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.molimm.2005.12.004","volume":"43","author":"KW Lee","year":"2006","unstructured":"Lee, K. W. et al. Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA. Mol. Immunol. 43, 2107\u20132118 (2006).","journal-title":"Mol. Immunol."},{"key":"346_CR86","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03968-5","volume":"9","author":"K Thomas-White","year":"2018","unstructured":"Thomas-White, K. et al. Culturing of female bladder bacteria reveals an interconnected urogenital microbiota. Nat. Commun. 9, 1557 (2018).","journal-title":"Nat. Commun."},{"key":"346_CR87","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12866-015-0578-2","volume":"15","author":"S Meshkibaf","year":"2015","unstructured":"Meshkibaf, S., Fritz, J., Gottschalk, M. & Kim, S. O. Preferential production of G-CSF by a protein-like Lactobacillus rhamnosus GR-1 secretory factor through activating TLR2-dependent signaling events without activation of JNKs. BMC Microbiol. 15, 238 (2015).","journal-title":"BMC Microbiol."},{"key":"346_CR88","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1128\/IAI.71.8.4238-4249.2003","volume":"71","author":"J Uehori","year":"2003","unstructured":"Uehori, J. et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette\u2013Guerin peptidoglycan. Infect. Immun. 71, 4238\u20134249 (2003).","journal-title":"Infect. Immun."},{"key":"346_CR89","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.1128\/IAI.68.12.6883-6890.2000","volume":"68","author":"S Tsuji","year":"2000","unstructured":"Tsuji, S. et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette\u2013Guerin: involvement of Toll-like receptors. Infect. Immun. 68, 6883\u20136890 (2000).","journal-title":"Infect. Immun."},{"key":"346_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000289","volume":"5","author":"C Astarie-Dequeker","year":"2009","unstructured":"Astarie-Dequeker, C. et al. Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids. PLoS Pathog. 5, e1000289 (2009).","journal-title":"PLoS Pathog."},{"key":"346_CR91","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fimmu.2018.00002","volume":"9","author":"R Oldenburg","year":"2018","unstructured":"Oldenburg, R. et al. Mycobacterial phenolic glycolipids selectively disable TRIF-dependent TLR4 signaling in macrophages. Front. Immunol. 9, 2 (2018).","journal-title":"Front. Immunol."},{"key":"346_CR92","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1021\/acschembio.6b00568","volume":"11","author":"A Arbues","year":"2016","unstructured":"Arbues, A. et al. Trisaccharides of phenolic glycolipids confer advantages to pathogenic mycobacteria through manipulation of host\u2013cell pattern-recognition receptors. ACS Chem. Biol. 11, 2865\u20132875 (2016).","journal-title":"ACS Chem. Biol."},{"key":"346_CR93","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejphar.2012.11.058","volume":"701","author":"H Kohka Takahashi","year":"2013","unstructured":"Kohka Takahashi, H. et al. Role of cell\u2013cell interactions in high mobility group Box 1 cytokine activity in human peripheral blood mononuclear cells and mouse splenocytes. Eur. J. Pharmacol. 701, 194\u2013202 (2013).","journal-title":"Eur. J. Pharmacol."},{"key":"346_CR94","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","volume":"192","author":"U Andersson","year":"2000","unstructured":"Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565\u2013570 (2000).","journal-title":"J. Exp. Med."},{"key":"346_CR95","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1189\/jlb.0108030","volume":"84","author":"RK Aneja","year":"2008","unstructured":"Aneja, R. K. et al. Preconditioning with high mobility group Box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance. J. Leukoc. Biol. 84, 1326\u20131334 (2008).","journal-title":"J. Leukoc. Biol."},{"key":"346_CR96","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.juro.2013.01.050","volume":"190","author":"G Zhang","year":"2013","unstructured":"Zhang, G. et al. HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette\u2013Guerin functions as a paracrine factor to potentiate the direct cellular effects of bacillus Calmette\u2013Guerin. J. Urol. 190, 1076\u20131082 (2013).","journal-title":"J. Urol."},{"key":"346_CR97","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.juro.2013.03.123","volume":"190","author":"G Zhang","year":"2013","unstructured":"Zhang, G., Chen, F., Cao, Y. & See, W. A. Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette\u2013Guerin. J. Urol. 190, 1398\u20131403 (2013).","journal-title":"J. Urol."},{"key":"346_CR98","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.juro.2015.11.073","volume":"195","author":"G Shah","year":"2016","unstructured":"Shah, G. et al. The dose\u2013response relationship of bacillus Calmette\u2013Guerin and urothelial carcinoma cell biology. J. Urol. 195, 1903\u20131910 (2016).","journal-title":"J. Urol."},{"key":"346_CR99","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/j.1464-410X.2008.08274.x","volume":"103","author":"WA See","year":"2009","unstructured":"See, W. A. et al. Bacille Calmette\u2013Guerin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group Box protein 1. BJU Int. 103, 1714\u20131720 (2009).","journal-title":"BJU Int."},{"key":"346_CR100","volume":"10","author":"B Chen","year":"2015","unstructured":"Chen, B. et al. S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One 10, e0115828 (2015).","journal-title":"PLoS One"},{"key":"346_CR101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/pmic.200500033","volume":"6","author":"JP Tolson","year":"2006","unstructured":"Tolson, J. P. et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6, 697\u2013708 (2006).","journal-title":"Proteomics"},{"key":"346_CR102","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molcel.2011.07.037","volume":"44","author":"IS Afonina","year":"2011","unstructured":"Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol. Cell 44, 265\u2013278 (2011).","journal-title":"Mol. Cell"},{"key":"346_CR103","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","volume":"17","author":"NC Di Paolo","year":"2016","unstructured":"Di Paolo, N. C. & Shayakhmetov, D. M. Interleukin 1alpha and the inflammatory process. Nat. Immunol. 17, 906\u2013913 (2016).","journal-title":"Nat. Immunol."},{"key":"346_CR104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2015.04.001","volume":"335","author":"S Grimm","year":"2015","unstructured":"Grimm, S. et al. Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine\u2013chemokine loop. Exp. Cell Res. 335, 1\u201311 (2015).","journal-title":"Exp. Cell Res."},{"key":"346_CR105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2009.10.020","volume":"46","author":"M Garg","year":"2010","unstructured":"Garg, M. et al. Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. Eur. J. Cancer 46, 207\u2013215 (2010).","journal-title":"Eur. J. Cancer"},{"key":"346_CR106","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.urolonc.2011.07.007","volume":"31","author":"HM Behnsawy","year":"2013","unstructured":"Behnsawy, H. M., Miyake, H., Kusuda, Y. & Fujisawa, M. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells. Urologic Oncol. 31, 843\u2013848 (2013).","journal-title":"Urologic Oncol."},{"key":"346_CR107","doi-asserted-by":"crossref","first-page":"15107","DOI":"10.1074\/jbc.M111204200","volume":"277","author":"RM Vabulas","year":"2002","unstructured":"Vabulas, R. M. et al. HSP70 as endogenous stimulus of the Toll\/interleukin-1 receptor signal pathway. J. Biol. Chem. 277, 15107\u201315112 (2002).","journal-title":"J. Biol. Chem."},{"key":"346_CR108","doi-asserted-by":"crossref","first-page":"30393","DOI":"10.1074\/jbc.M111.266528","volume":"286","author":"H Fang","year":"2011","unstructured":"Fang, H. et al. Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response. J. Biol. Chem. 286, 30393\u201330400 (2011).","journal-title":"J. Biol. Chem."},{"key":"346_CR109","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yexcr.2012.09.018","volume":"319","author":"KH Lee","year":"2013","unstructured":"Lee, K. H., Jeong, J. & Yoo, C. G. Positive feedback regulation of heat shock protein 70 (Hsp70) is mediated through Toll-like receptor 4-PI3K\/Akt-glycogen synthase kinase-3beta pathway. Exp. Cell Res. 319, 88\u201395 (2013).","journal-title":"Exp. Cell Res."},{"key":"346_CR110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/imr.12577","volume":"280","author":"Z Yang Han","year":"2017","unstructured":"Yang Han, Z. & Oppenheim, J. J. Alarmins and immunity. Immunol. Rev. 280, 41\u201356 (2017).","journal-title":"Immunol. Rev."},{"key":"346_CR111","first-page":"5","volume":"38","author":"MJ Daniels","year":"2020","unstructured":"Daniels, M. J. et al. Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urologic Oncol. 38, 5 (2020).","journal-title":"Urologic Oncol."},{"key":"346_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066","author":"MO Grimm","year":"2020","unstructured":"Grimm, M. O. et al. Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial \u2018NIMBUS\u2019. Eur. Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.066 (2020).","journal-title":"Eur. Urol."},{"key":"346_CR113","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens, J. et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette\u2013Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 63, 462\u2013472 (2013).","journal-title":"Eur. Urol."},{"key":"346_CR114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat, A. M. et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat. Rev. Urol. 12, 225\u2013235 (2015).","journal-title":"Nat. Rev. Urol."},{"key":"346_CR115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2019.10.021","volume":"18","author":"D D\u2019Andrea","year":"2020","unstructured":"D\u2019Andrea, D. et al. Comparative effectiveness of intravesical BCG-Tice and BCG-Moreau in patients with non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer 18, 20\u201325 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"346_CR116","first-page":"306","volume":"36","author":"N Niwa","year":"2018","unstructured":"Niwa, N. et al. Does switching the bacillus Calmette\u2013Guerin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette\u2013Guerin therapy? Urologic Oncol. 36, 306 (2018).","journal-title":"Urologic Oncol."},{"key":"346_CR117","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000492722","volume":"101","author":"W Krajewski","year":"2018","unstructured":"Krajewski, W. et al. Are there differences in toxicity and efficacy between various bacillus Calmette\u2013Guerin strains in bladder cancer patients? Analysis of 844 patients. Urol. Int. 101, 277\u2013284 (2018).","journal-title":"Urol. Int."},{"key":"346_CR118","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.juro.2017.12.057","volume":"199","author":"N Niwa","year":"2018","unstructured":"Niwa, N. et al. Purified protein derivative skin test prior to bacillus Calmette\u2013Guerin therapy may have therapeutic impact in patients with nonmuscle invasive bladder cancer. J. Urol. 199, 1446\u20131451 (2018).","journal-title":"J. Urol."},{"key":"346_CR119","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000440701","volume":"96","author":"SL Hofbauer","year":"2016","unstructured":"Hofbauer, S. L. et al. The Moreau strain of bacillus Calmette\u2013Guerin (BCG) for high-risk non-muscle invasive bladder cancer: an alternative during worldwide BCG shortage? Urol. Int. 96, 46\u201350 (2016).","journal-title":"Urol. Int."},{"key":"346_CR120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","volume":"10","author":"C Gan","year":"2013","unstructured":"Gan, C., Mostafid, H., Khan, M. S. & Lewis, D. J. BCG immunotherapy for bladder cancer \u2014 the effects of substrain differences. Nat. Rev. Urol. 10, 580\u2013588 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"346_CR121","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","volume":"198","author":"BE Boehm","year":"2017","unstructured":"Boehm, B. E. et al. Efficacy of bacillus Calmette\u2013Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis. J. Urol. 198, 503\u2013510 (2017).","journal-title":"J. Urol."},{"key":"346_CR122","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.urolonc.2016.05.033","volume":"34","author":"JA Witjes","year":"2016","unstructured":"Witjes, J. A. et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol. Oncol. 34, 484 (2016).","journal-title":"Urol. Oncol."},{"key":"346_CR123","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.juro.2013.12.002","volume":"191","author":"S Secanella-Fandos","year":"2014","unstructured":"Secanella-Fandos, S., Noguera-Ortega, E., Olivares, F., Luquin, M. & Julian, E. Killed but metabolically active Mycobacterium bovis bacillus Calmette\u2013Guerin retains the antitumor ability of live bacillus Calmette\u2013Guerin. J. Urol. 191, 1422\u20131428 (2014).","journal-title":"J. Urol."},{"key":"346_CR124","first-page":"6230409","volume":"2019","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Lu, J., Huang, Y. & Ma, L. Clinical spectrum of complications induced by intravesical immunotherapy of bacillus Calmette\u2013Guerin for bladder cancer. J. Oncol. 2019, 6230409 (2019).","journal-title":"J. Oncol."},{"key":"346_CR125","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s13691-018-0342-1","volume":"7","author":"T Nakagawa","year":"2018","unstructured":"Nakagawa, T. et al. Reiter\u2019s syndrome following intravesical bacillus Calmette\u2013Guerin therapy for bladder carcinoma: a report of five cases. Int. Cancer Conf. J. 7, 148\u2013151 (2018).","journal-title":"Int. Cancer Conf. J."},{"key":"346_CR126","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fimmu.2018.00298","volume":"9","author":"RJW Arts","year":"2018","unstructured":"Arts, R. J. W., Joosten, L. A. B. & Netea, M. G. The potential role of trained immunity in autoimmune and autoinflammatory disorders. Front. Immunol. 9, 298 (2018).","journal-title":"Front. Immunol."},{"key":"346_CR127","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/imr.12833","volume":"294","author":"G Cab\u0103u","year":"2020","unstructured":"Cab\u0103u, G., Cri\u0219an, T. O., Kl\u00fcck, V., Popp, R. A. & Joosten, L. A. B. Urate-induced immune programming: consequences for gouty arthritis and hyperuricemia. Immunol. Rev. 294, 92\u2013105 (2020).","journal-title":"Immunol. Rev."},{"key":"346_CR128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fcimb.2014.00173","volume":"4","author":"A Arbues","year":"2014","unstructured":"Arbues, A., Lugo-Villarino, G., Neyrolles, O., Guilhot, C. & Astarie-Dequeker, C. Playing hide-and-seek with host macrophages through the use of mycobacterial cell envelope phthiocerol dimycocerosates and phenolic glycolipids. Front. Cell. Infect. Microbiol. 4, 173 (2014).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"346_CR129","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature12799","volume":"505","author":"CJ Cambier","year":"2014","unstructured":"Cambier, C. J. et al. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 505, 218\u2013222 (2014).","journal-title":"Nature"},{"key":"346_CR130","doi-asserted-by":"crossref","first-page":"405310","DOI":"10.1155\/2011\/405310","volume":"2011","author":"J Kleinnijenhuis","year":"2011","unstructured":"Kleinnijenhuis, J., Oosting, M., Joosten, L. A., Netea, M. G. & Van Crevel, R. Innate immune recognition of Mycobacterium tuberculosis. Clin. Dev. Immunol. 2011, 405310 (2011).","journal-title":"Clin. Dev. Immunol."},{"key":"346_CR131","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1016\/j.vaccine.2007.09.041","volume":"25","author":"JM Chen","year":"2007","unstructured":"Chen, J. M., Islam, S. T., Ren, H. & Liu, J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 25, 8114\u20138122 (2007).","journal-title":"Vaccine"},{"key":"346_CR132","first-page":"612","volume":"15","author":"CA Dinarello","year":"2019","unstructured":"Dinarello, C. A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nature reviews. Rheumatology 15, 612\u2013632 (2019).","journal-title":"Rheumatology"},{"key":"346_CR133","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cell.2018.11.007","volume":"175","author":"MG Netea","year":"2018","unstructured":"Netea, M. G. & Joosten, L. A. B. Trained immunity and local innate immune memory in the lung. Cell 175, 1463\u20131465 (2018).","journal-title":"Cell"},{"key":"346_CR134","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.cell.2018.09.042","volume":"175","author":"Y Yao","year":"2018","unstructured":"Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 175, 1634\u20131650 (2018).","journal-title":"Cell"},{"key":"346_CR135","first-page":"458","volume":"16","author":"W Krajewski","year":"2019","unstructured":"Krajewski, W. et al. Does Mantoux test results predict BCG immunotherapy efficiency and severe toxicity in non-muscle invasive bladder cancer. Urol. J. 16, 458\u2013462 (2019).","journal-title":"Urol. J."},{"key":"346_CR136","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","volume":"4","author":"RS Svatek","year":"2018","unstructured":"Svatek, R. S., Tangen, C., Delacroix, S., Lowrance, W. & Lerner, S. P. Background and update for S1602 \u2018A phase III randomized trial to evaluate the influence of BCG strain differences and T cell priming with intradermal BCG before intravesical therapy for BCG-naive high-grade non-muscle-invasive bladder cancer\u2019. Eur. Urol. Focus. 4, 522\u2013524 (2018).","journal-title":"Eur. Urol. Focus."},{"key":"346_CR137","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cell.2016.09.034","volume":"167","author":"B Novakovic","year":"2016","unstructured":"Novakovic, B. et al. Beta-glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354\u20131368 (2016).","journal-title":"Cell"},{"key":"346_CR138","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1189\/jlb.5RI0217-064RR","volume":"102","author":"MG Netea","year":"2017","unstructured":"Netea, M. G., Joosten, L. A. B. & van der Meer, J. W. M. Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. J. Leukoc. Biol. 102, 1323\u20131332 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"346_CR139","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-019-0025-4","volume":"18","author":"WJM Mulder","year":"2019","unstructured":"Mulder, W. J. M., Ochando, J., Joosten, L. A. B., Fayad, Z. A. & Netea, M. G. Therapeutic targeting of trained immunity. Nat. Rev. Drug Discov. 18, 553\u2013566 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"346_CR140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","volume":"128","author":"ES Larsen","year":"2020","unstructured":"Larsen, E. S., Joensen, U. N., Poulsen, A. M., Goletti, D. & Johansen, I. S. Bacillus Calmette\u2013Guerin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. Apmis 128, 92\u2013103 (2020).","journal-title":"Apmis"},{"key":"346_CR141","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cell.2007.05.059","volume":"129","author":"N van der Wel","year":"2007","unstructured":"van der Wel, N. et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287\u20131298 (2007).","journal-title":"Cell"},{"key":"346_CR142","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.juro.2013.09.012","volume":"191","author":"G Shah","year":"2014","unstructured":"Shah, G. et al. Loss of bacillus Calmette\u2013Guerin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette\u2013Guerin exposure. J. Urol. 191, 823\u2013829 (2014).","journal-title":"J. Urol."},{"key":"346_CR143","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euf.2015.03.003","volume":"2","author":"E Noguera-Ortega","year":"2016","unstructured":"Noguera-Ortega, E. et al. Nonpathogenic Mycobacterium brumae inhibits bladder cancer growth in vitro, ex vivo, and in vivo. Eur. Urol. Focus 2, 67\u201376 (2016).","journal-title":"Eur. Urol. Focus"},{"key":"346_CR144","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1756287215607818","volume":"8","author":"VT Packiam","year":"2016","unstructured":"Packiam, V. T., Pearce, S. M. & Steinberg, G. D. The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette\u2013Guerin failures for non-muscle-invasive bladder cancer. Ther. Adv. Urol. 8, 29\u201337 (2016).","journal-title":"Ther. Adv. Urol."},{"key":"346_CR145","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","volume":"193","author":"A Morales","year":"2015","unstructured":"Morales, A. et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette\u2013Guerin. J. Urol. 193, 1135\u20131143 (2015).","journal-title":"J. Urol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-0346-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-0346-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41585-020-0346-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:44:22Z","timestamp":1684604662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-020-0346-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":145,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1038\/s41585-020-0346-4","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"assertion":[{"value":"3 June 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A.B.J. and M.G.N. declare that they are scientific founders of Trained Therapeutics Discovery and are the owners of two patents related to trained immunity. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}